CM
ADAP

Crestline Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Crestline Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,489
Closed -$67K – 203
2022
Q2 		$67K Sell
39,489
-511
-1% -$878 0.01% 216
2022
Q1 		$82K Buy
+40,000
New +$108K 0.01% 253

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crestline Management's ADAP Position: Q3 2022 in Review

Crestline Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 39,489 shares — an estimated $67K sold.

Crestline Management first reported a position in ADAP in Q1 2022 and held it in 2 quarters. The position peaked at $82K in Q1 2022. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Crestline Management reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 39,489 Adaptimmune Therapeutics shares in Q3 2022, an estimated $67K.
  • Crestline Management first reported a position in Adaptimmune Therapeutics in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Adaptimmune Therapeutics position peaked at $82K in Q1 2022.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.